Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217654 | 0.94 | USP30 (0.44) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5342029 | 0.91 | GPR119 (0.48) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5253946 | 0.89 | CHEK2 (0.44) | GPR119PDE4BMEN1KMT2ACHEK2 | |
| SCHEMBL6706491 | 0.85 | PLA2G4B (0.46) | GPR119MEN1KMT2A | |
| SCHEMBL5214477 | 0.84 | GPR119 (0.42) | GPR119MEN1KMT2ACHEK2 | |
| SCHEMBL215338 | 0.84 | GPR119 (0.54) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5215797 | 0.83 | GPR119 (0.44) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL27087822 | 0.82 | GPR119 (0.54) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6189754 | 0.81 | GPR119 (0.64) | GPR119CHEK2 | |
| SCHEMBL1447329 | 0.81 | GPR119 (0.54) | GPR119PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | GPR119 1394/4885PDE4D 4500/4885PDE4B 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.